The University of Chicago Header Logo

Connection

Theodore Karrison to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications Theodore Karrison has written about Aged, 80 and over.
Theodore Karrison
Connection Strength
1.012
Aged, 80 and over
  1. Effects of driving distance and transport time on mortality among Level I and II traumas occurring in a metropolitan area. J Trauma Acute Care Surg. 2018 Oct; 85(4):756-765.
    View in: PubMed
    Score: 0.073
  2. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
    View in: PubMed
    Score: 0.066
  3. Modeling major lung resection outcomes using classification trees and multiple imputation techniques. Eur J Cardiothorac Surg. 2008 Nov; 34(5):1085-9.
    View in: PubMed
    Score: 0.036
  4. A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.
    View in: PubMed
    Score: 0.028
  5. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
    View in: PubMed
    Score: 0.028
  6. Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol. 2024 Dec; 42(34):4095-4102.
    View in: PubMed
    Score: 0.027
  7. Underlying intracranial atherosclerotic disease is associated with worse outcomes in acute large vessel occlusion undergoing endovascular thrombectomy. J Stroke Cerebrovasc Dis. 2023 Aug; 32(8):107227.
    View in: PubMed
    Score: 0.025
  8. The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. Int J Radiat Oncol Biol Phys. 2022 10 01; 114(2):266-274.
    View in: PubMed
    Score: 0.023
  9. Sizes of ruptured and unruptured aneurysms in relation to their sites and the ages of patients. J Neurosurg. 2002 Jan; 96(1):64-70.
    View in: PubMed
    Score: 0.023
  10. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.022
  11. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 08 20; 39(24):2647-2655.
    View in: PubMed
    Score: 0.022
  12. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
    View in: PubMed
    Score: 0.021
  13. A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. Cancer. 2020 07 15; 126(14):3237-3243.
    View in: PubMed
    Score: 0.020
  14. Does pneumonectomy for lung cancer adversely influence long-term survival? J Thorac Cardiovasc Surg. 2000 Mar; 119(3):440-8.
    View in: PubMed
    Score: 0.020
  15. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 2020 05 15; 126(10):2146-2152.
    View in: PubMed
    Score: 0.020
  16. Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
    View in: PubMed
    Score: 0.020
  17. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clin Cancer Res. 2020 01 01; 26(1):18-24.
    View in: PubMed
    Score: 0.019
  18. Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. J Clin Pharmacol. 2019 12; 59(12):1632-1640.
    View in: PubMed
    Score: 0.019
  19. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
    View in: PubMed
    Score: 0.019
  20. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
    View in: PubMed
    Score: 0.019
  21. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
    View in: PubMed
    Score: 0.018
  22. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395.
    View in: PubMed
    Score: 0.018
  23. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.017
  24. Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol. 2018 04; 31(4):598-606.
    View in: PubMed
    Score: 0.017
  25. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
    View in: PubMed
    Score: 0.016
  26. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 2016 06 20; 34(18):2165-71.
    View in: PubMed
    Score: 0.015
  27. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
    View in: PubMed
    Score: 0.015
  28. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93.
    View in: PubMed
    Score: 0.015
  29. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. Clin Cancer Res. 2015 Nov 15; 21(22):5092-9.
    View in: PubMed
    Score: 0.015
  30. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015 Apr; 33(2):371-9.
    View in: PubMed
    Score: 0.014
  31. Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades. Ann Oncol. 2015 Jan; 26(1):198-205.
    View in: PubMed
    Score: 0.014
  32. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
    View in: PubMed
    Score: 0.014
  33. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
    View in: PubMed
    Score: 0.013
  34. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
    View in: PubMed
    Score: 0.012
  35. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. Cancer. 2013 May 01; 119(9):1683-9.
    View in: PubMed
    Score: 0.012
  36. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun; 31(3):769-73.
    View in: PubMed
    Score: 0.012
  37. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
    View in: PubMed
    Score: 0.011
  38. Efficacy of daily routine chest radiographs in intubated, mechanically ventilated patients. Crit Care Med. 1991 May; 19(5):689-93.
    View in: PubMed
    Score: 0.011
  39. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol. 2011 Apr; 34(2):150-4.
    View in: PubMed
    Score: 0.011
  40. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.
    View in: PubMed
    Score: 0.011
  41. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol. 2010 Nov 01; 28(31):4740-6.
    View in: PubMed
    Score: 0.010
  42. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010 Jun 01; 28(16):2653-9.
    View in: PubMed
    Score: 0.010
  43. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.
    View in: PubMed
    Score: 0.010
  44. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009 Jul; 56(1):97-103.
    View in: PubMed
    Score: 0.009
  45. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
    View in: PubMed
    Score: 0.009
  46. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.009
  47. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug; 44(12):1684-92.
    View in: PubMed
    Score: 0.009
  48. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
    View in: PubMed
    Score: 0.009
  49. Reproducibility and sources of variability in radiographic texture analysis of densitometric calcaneal images. J Clin Densitom. 2008 Apr-Jun; 11(2):211-20.
    View in: PubMed
    Score: 0.009
  50. Radiographic texture analysis of densitometer-generated calcaneus images differentiates postmenopausal women with and without fractures. Osteoporos Int. 2006 Oct; 17(10):1472-82.
    View in: PubMed
    Score: 0.008
  51. A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther. 2006 Jul; 5(7):766-70.
    View in: PubMed
    Score: 0.008
  52. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Invest New Drugs. 2006 Mar; 24(2):141-9.
    View in: PubMed
    Score: 0.008
  53. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
    View in: PubMed
    Score: 0.007
  54. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
    View in: PubMed
    Score: 0.007
  55. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res. 2004 May 15; 10(10):3365-70.
    View in: PubMed
    Score: 0.007
  56. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
    View in: PubMed
    Score: 0.007
  57. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
    View in: PubMed
    Score: 0.006
  58. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
    View in: PubMed
    Score: 0.006
  59. Early revisit, hospitalization, or death among older persons discharged from the ED. Am J Emerg Med. 2001 Mar; 19(2):125-9.
    View in: PubMed
    Score: 0.005
  60. Older patients' health-related quality of life around an episode of emergency illness. Ann Emerg Med. 1999 Nov; 34(5):595-603.
    View in: PubMed
    Score: 0.005
  61. The effect of alcohol abuse on the health status of older adults seen in the emergency department. Am J Drug Alcohol Abuse. 1999 Aug; 25(3):529-42.
    View in: PubMed
    Score: 0.005
  62. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 1997 May; 49(5):697-702.
    View in: PubMed
    Score: 0.004
  63. Randomized, prospective, double-blind study of the effects on pain perception of lidocaine jelly versus plain lubricant during outpatient rigid cystoscopy. J Urol. 1997 Jan; 157(1):90-4.
    View in: PubMed
    Score: 0.004
  64. Hospital utilization patterns and costs for adult sickle cell patients in Illinois. Public Health Rep. 1997 Jan-Feb; 112(1):44-51.
    View in: PubMed
    Score: 0.004
  65. Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques. Int J Radiat Oncol Biol Phys. 1993 Jan 15; 25(2):359-71.
    View in: PubMed
    Score: 0.003
  66. Localized prostate cancer: use of serial prostate-specific antigen measurements during radiation therapy. Radiology. 1992 Jul; 184(1):271-4.
    View in: PubMed
    Score: 0.003
  67. Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer. 1987 May 15; 59(10):1744-50.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.